Pharma Tech Holdings SA Obtains a Capital Commitment Agreement of CHF 30 million from Global Investor LDA Capital
Pharma Tech Holding SA (“PTH”) announced today it has secured a CHF 30 million investment to support its portfolio investments from LDA Capital Ltd, a global investment group with expertise in cross border transactions including the agriculture, Agri-tech, and CBD industries.
Established in 2019, PTH is a Swiss based holding company, which invests into innovative businesses with high technological value and scalability potential, mainly in Switzerland and Europe, with a focus on the health-tech, Agri-tech, and functional food.
This investment will allow PTH to mainly invest and support its portfolio company Blue Sky Swisse SA (“BSS”) a JV between PTH and listed company IGEA PHARMA NV (“Igea”), IGPH - ISIN NL0012768675. BSS focuses on the extraction of natural active principles from vegetable matrices, vegetable waste, and renewable sources to deliver B2B products under the form of CBD oil, Terpenes and Waxes. The factory located in Biasca, will be built to the state of art of extraction technology by super critical CO2 and will be energy self-sufficient through the use of solar photovoltaic panels and district heating. BSS will grant for highest CBD quality also due to a proprietary extraction process, starting from the farming performed under strict control and culminating with the immediate freezing of the flowers after harvest, with the target to also sell “all natural” formulations to increase bioavailability thus enhancing the possible applications. Last, but not least, BSS will invest in the agricultural raw material chain and will create an aeroponic green house in Ticino, to deliver a high quality GMP Pharmaceutical CBD oil.
LDA Capital agreed to commit an amount of up to CHF 30 million (the “Capital Commitment”) in cash within a maximum of three years. This Capital Commitment will be released based on drawdowns by PTH, that PTH has the right to exercise at its sole discretion.
“We’re thrilled with this partnership and are so glad that LDA Capital recognizes the value of PTH and its portfolio company, with the aim of creating one of the most innovative hub for health-tech, agri-tech and functional food,” said Sabina Del Nigro, CEO at PTH.
About Pharma Tech Holding: Pharma Tech Holding SA (PTH) is a holding company based in Lugano, Switzerland, which invests into innovative businesses with high technological value and scalability potential, mainly in Switzerland and Europe, with a focus on the health-tech, Agri-tech, and functional food.
About LDA Capital: LDA Capital is a global alternative investment group with expertise in cross border transactions worldwide. Our team has dedicated their careers to international & cross border opportunities having collectively executed over 250 transactions in both the public and private middle markets across 43 countries with aggregate transaction values of over US$11 billion. For more information please visit: www.ldacap.com; for inquiries please email: info@ldacap.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220808005153/en/
Contact information
Sabina Del Nigro
Pharma Tech Holding SA
info@pharmatechholding.com
LDA Capital Ltd
info@ldacap.com
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Interactive Brokers Launches Daily Options on the CAC 40 ® Index2.5.2024 16:00:00 CEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global electronic broker, today announced the availability of Daily Options on the CAC 40® index, further expanding Interactive Brokers’ robust product suite. Daily Options on the CAC 40® index provide experienced investors with another means to execute short-term trading strategies and manage exposure to the French stock market. Milan Galik, Chief Executive Officer of Interactive Brokers, commented on the launch, "We are pleased to offer Daily Options on the CAC 40® index, which will allow our clients to balance risk and swiftly adjust their portfolios in response to market movements. At Interactive Brokers, we strive to equip our clients with an array of products to find global opportunities, and this new offering underscores our commitment to providing traders with comprehensive product solutions.” Daily Options on the CAC 40® index cater to growing demand from institutional and retail investors for options with daily expirations. The
AMRA Medical’s Muscle Composition Analysis Used to Evaluate the Effect of Liraglutide Treatment in Obesity2.5.2024 15:35:00 CEST | Press release
AMRA Medical - a health informatics and precision medicine company that is pioneering body composition research through gold-standard MRI-based analysis platforms - collaborated on a study driven by University of Texas Southwestern and University Hospital Cleveland to publish new data revealing the effect of liraglutide treatment on muscle composition in adults with obesity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502719692/en/ Credit: Collaboration with Dr. Ian J Neeland, University Hospitals Cleveland. Data from NCT03038620 (ClinicalTrials.gov identifier) analysed with AMRA® Researcher The analysis included 128 diabetes-free adults with obesity who received a lifestyle intervention in addition to being randomized to either a liraglutide (n = 73) or a placebo (n = 55) treatment group. Using the proprietary MRI-based AMRAⓇ Researcher, baseline and follow-up muscle composition analyses were performed, with the prima
Brightcove Integrates New AWS-Powered Generative AI Solution to Enhance Its Award-Winning Customer Service2.5.2024 15:00:00 CEST | Press release
Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, today shared it has implemented Amazon Q Business, a new generative AI assistant on Amazon Web Services (AWS). Using its own public documentation, product, and release notes, Brightcove is leveraging the new assistant internally for real-world use cases applicable to the media and entertainment technology sector. Brightcove is tapping into the technology to build a program to equip its global services and customer success team to further bolster its award-winning customer service. As an early adopter of Amazon Q, Brightcove has launched the “Brightcove Expert Bot,” an AI-powered chatbot embedded into the internal tools, as a new resource for the customer and product support teams. Streamlining its customer support processes enables employees to quickly and effectively find relevant information, solve technical cases, analyze support requests, summarize support tickets, and use those results to help recomm
Power2Drive Europe: Contributing to the Energy Transition With Bidirectional Charging2.5.2024 14:39:00 CEST | Press release
E-mobility is about much more than driving on climate-neutral electricity from renewable sources. The batteries of electric vehicles can be used as temporary storage. And it’s not just vehicle owners who benefit from this: In the medium-term, bidirectional charging can take the burden off distribution grids while making them more flexible. Power2Drive Europe, the international exhibition for charging infrastructure and e-mobility, showcases the latest state of the art. As part of The smarter E Europe, the continent’s largest alliance of exhibitions for the energy industry, it will take place from June 19–21, 2024, at Messe München. The Power2Drive Europe Conference, the industry's meeting point and forum for exchange and discourse among experts, stakeholders, and thought leaders in the new mobility sector, kicks off one day earlier. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502196803/en/ Power2Drive Europe 2024 highl
Owlet Announces European Medical Certification of Dream Sock Ⓡ2.5.2024 14:37:00 CEST | Press release
Owlet, Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, announces the EU medical device certification of Dream Sock. This EU-CE-Mark certification, issued by Owlet’s EU notified body, signifies that Owlet’s Dream Sock has been assessed and certified to meet safety and health requirements set out under EU medical device legislation. With this certification, Owlet plans to expand its medical-device product portfolio to even more caregivers around the world. This EU medical device certification follows two marketing authorizations from the U.S. Food and Drug Administration (the “FDA”), for Dream Sock, with new medical technology for healthy infants over-the-counter without a prescription, and for BabySatⓇ, a prescription-only pulse oximeter designed for use with babies that have a pre-existing medical condition. “Our mission to be there for every parent and every baby becomes even more realized with the European medical certification for Dream Sock,” sa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom